Brookline, MA, March 22, 2010 — Tarix Phamaceuticals today announced that the University of Southern California has received an additional grant to study the effects of TXA127 in preventing thrombocytopenia following radiation exposure. This is a continuation of the original $1 million grant received in 2008.
The grant was awarded under Project Bioshield Authority, legislation that enables NIAID within the Department of Health and Human Services (HHS) to use a rapid award process to help stimulate research on medical countermeasures against chemical, biological, radiological or nuclear (CBRN) threats. Under the initial grant, an appropriate dose was determined. The new grant will fund the completion of these studies in preparation for further government funding taking the product through to approval.
“We are very pleased with this vote of confidence, and look forward to continuing our close relationship with NIAID and other agencies to bring this product to completion”, said Dr Richard Franklin, CEO of Tarix Pharmaceuticals.
The principle investigator is Dr. Kathleen Rodgers, a Professor at Keck-USC School of Medicine.
This entry was posted in News & Events. Bookmark the
permalink. Both comments and trackbacks are currently closed.
University of Southern California receives additional grant to study TXA127 for the prevention of radiation damage
Brookline, MA, March 22, 2010 — Tarix Phamaceuticals today announced that the University of Southern California has received an additional grant to study the effects of TXA127 in preventing thrombocytopenia following radiation exposure. This is a continuation of the original $1 million grant received in 2008.
The grant was awarded under Project Bioshield Authority, legislation that enables NIAID within the Department of Health and Human Services (HHS) to use a rapid award process to help stimulate research on medical countermeasures against chemical, biological, radiological or nuclear (CBRN) threats. Under the initial grant, an appropriate dose was determined. The new grant will fund the completion of these studies in preparation for further government funding taking the product through to approval.
“We are very pleased with this vote of confidence, and look forward to continuing our close relationship with NIAID and other agencies to bring this product to completion”, said Dr Richard Franklin, CEO of Tarix Pharmaceuticals.
The principle investigator is Dr. Kathleen Rodgers, a Professor at Keck-USC School of Medicine.